Загрузка...
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte–macrophage colony-stimulating factor (GM-CSF). Overall response rate w...
Сохранить в:
| Опубликовано в: : | Cancer Immunol Immunother |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445176/ https://ncbi.nlm.nih.gov/pubmed/28238174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-1967-1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|